霍奇金淋巴瘤R-S细胞PTEN基因的表达与意义

目的：研究PTEN基因在霍奇金淋巴瘤（Hodgkin＇s lymphoma,HL）R-S细胞中的表达和意义。方法：PCR检测HL R-S细胞PTEN基因的外显子以证明PTEN基因是否存在,用原位杂交和免疫组化染色方法检测HL R-S细胞PTEN的表达。结果：20例HL中,PCR均检测到PTEN基因的3、4、5外显子,75.0%（15/20）HL R-S细胞中表达PTEN mRNA较强,同样地,70.0%（14/20）HL R-S细胞中PTEN蛋白表达强,而周围小的淋巴细胞不表达或弱表达PTEN mRNA和PTEN蛋白。结论：PTEN的强表达与R-S细胞形成有密切的关系。     

两次自体外周血造血干细胞移植治疗复发难治性非霍奇金淋巴瘤的临床研究

目的 探讨两次自体外周血造血干细胞移植(auto-PBSCT)治疗复发难治性非霍淋巴瘤的疗效和安全性.方法 确诊的复发难治性非霍奇金淋巴瘤(NHL)患者6例,其中男5例,女1例,年龄34～67岁,平均52岁.患者选择标准:经一次auto-PBSCT术后复发或未达完全缓解,予以再次动员干细胞行第二次移植;分期Ⅲ～Ⅳ期的侵袭性淋巴瘤患者,首次auto-PBSCT不能达完全缓解,或复发可能性大,于第一次动员干细胞达两次移植所需,且第一次移植术后半年行第二次auto-PBSCT移植.结果 6例患者均能耐受预处理,并获得造血功能重建,移植后外周血中性粒细胞计数(ANC) ＞0.5×109/L的中位时间为15 d(10～25 d);血小板计数(BPC)大于20×109/L的中位时间25.8 d(12～57 d).全部患者中位随访时间22.7个月(3～50个月),1例患者两次移植术后半年因病毒性肝炎肝功能衰竭死亡,1例18个月后再次复发,二线治疗方案仍有效,其余4例患者无病生存,无病生存率66.7％,最长无病生存时间已达50个月.结论 两次auto-PBSCT治疗复发难治性NHL安全有效,患者耐受良好,值得在临床上进一步推广应用.     

PTTG 基因对非霍奇金淋巴瘤细胞增殖能力的影响

目的：观察垂体瘤转化基因（pituitary tumor-transforming gene ,PTTG）对非霍奇金淋巴瘤细胞SUDHL-4增殖能力的影响。方法通过shRNA的方法在高表达PTTG的SUDHL-4细胞中敲降PTTG基因,通过MTT实验、细胞周期分析检测SUDHL-4生物学行为的变化。结果 PTTG被敲降后SUDHL-4细胞的生长速度明显下降,细胞G0／G1比例、S期比例下降;G2／M期比例升高,细胞阻滞于G2／M期,差异均有统计学意义（P＜0.05）。结论 PTTG基因可能在非霍奇金淋巴瘤的发生发展中起重要作用,可能成为判断非霍奇金淋巴瘤预后的分子标志物及临床治疗的靶点。     

利妥昔单抗联合化疗治疗非霍奇金淋巴瘤的药物经济学评价

目的：系统评价利妥昔单抗联合化疗治疗非霍奇金淋巴瘤的药物经济学价值。方法：用计算机检索PubMed、ScienceDirect、Springer Link、Elsevier等英文数据库以及CNKI、维普、万方等中文数据库1998-2013年间公开发表的利妥昔单抗联合化疗治疗非霍奇金淋巴瘤的药物经济学评价文献,对文献质量、研究结果进行系统评价。结果：所有英文文献的ICER值均在各国的意愿支付范围内：国内外利妥昔单抗药物经济学评价在数据来源、研究方法等方面存在差异。结论：利妥昔单抗联合化疗治疗非霍奇金淋巴瘤在国外具有成本一效果;需开展高质量的研究来探索利妥昔单抗联合化疗治疗非霍奇金淋巴瘤在我国的经济性。     

Evaluation of the predictive role of neutrophil/lymphocyte ratio in the diagnosis of lymphoma in patients with asymptomatic and ısolated cervical lymphadenopathy

IntroductionThe diagnostic approach to patients with isolated asymptomatic cervical lymphadenopathy varies between excisional biopsy and follow-up. When the anamnesis, physical examination, laboratory and imaging findings are not sufficient to identify the etiology, an excisional biopsy is performed for the differential diagnosis between early-stage lymphoma and infectious or reactive causes. If the excisional biopsy, which may have some complications, is not performed, it may delay the diagnosis of lymphoma. This diagnostic challenge could be avoided by predictive markers.ObjectivesThis study was planned to determine the predictive value of neutrophil/lymphocyte ratio in the diagnosis of Hodgkin and non-Hodgkin limphoma in patients with asymptomatic, isolated cervical limphadenopathy and underwent excisional biopsy.MethodsA total of 90 patients between the years 2016 ? 2019 admitted to our clinics due to asymptomatic isolated cervical lymphadenopathy, present in at least 4 weeks with lympho nodes in pathological dimensions persisting in the cervical region, were included to our study. An excisional lympho node biopsy was performed in all 90 patients.ResultsOf the 90 patients who underwent excisional biopsy; 34 were diagnosed as reactive lymphadenopathy 30 were non-Hodgkin linphoma, and 26 were Hodgkin linphoma. A total of 56 (62.2%) patients were diagnosed as lymphoma, either Hodgkin or non-Hodgkin, while 34 patients (38.8%) were diagnosed as reactive lymphadenopathy. The median age, total whiteblood count, neutrophil count of the lymphoma groups were significantly higher than reactive lymphadenopathy group, whereas the lymphocyte count was significantly lower in the lymphoma patients. The median neutrophil/ lymphocyte ratio was 1.7 in the reactive lymphadenopathy group, 3.5 in the non-Hodgkin limphoma group, and 3.0 in the Hodgkin limphoma group (p <  0.001).ConclusionAccording to the results of our study, neutrophil/lymphocyte ratio was significantly higher in patients who were admitted with isolated asymptomatic lymphadenopathy and were diagnosed with lymphoma, and who were diagnosed with early-stage Hodgkin and non- Hodgkin lymphoma compared to those who were found to have reactive lymphadenopathy. Neutrophil/lymphocyte ratio, which is a low-cost, fast and easy-to-access test, has a predictive value in the diagnosis of lymphoma in patients with asymptomatic lymphadenopathy.     

Treatment Outcome of Chinese Children with Anaplastic Large Cell Lymphoma by Using a Modified B-NHL-BFM-90 Protocol

Pediatric anaplastic large cell lymphoma (ALCL) has rarely been reported in Chinese pediatric patients. This study evaluated the clinical characteristics and treatment outcome of Chinese pediatric patients with ALCL. Between October 2002 and October 2012, 39 untreated pediatric patients with ALCL were enrolled at a single institution. The patients were stratified into three groups (R1, R2, and R3) based on the stage of the disease, clinical risk factors, and chemotherapeutic response, and received different intensive chemotherapy regimens based on a modified B-NHL-BFM-90 protocol. Of the 39 patients, 22 were boys, and 17 were girls, with a median age at diagnosis of 10 years (range 2–16 years), 91.2% were anaplastic lymphoma kinase (ALK)-positive. The patient groups R1, R2, and R3 accounted for 12.8%, 30.4%, and 56.4% of the total, respectively. 87.2% of patients were stage III/IV. At a median follow-up period of 52 months (range 15–136 months), seven patients relapsed and three patients died of their disease. The 5-year event-free survival for all patients was 81.4% ± 6.4%, with 100%, 83.3% ± 10% and 75.3% ± 9.8% for groups R1, R2, and R3, respectively. The overall survival for all patients was 92.2% ± 4.3%. Our study demonstrates that a risk-stratified treatment with a modified B-NHL-BFM-90 protocol is efficacious for Chinese children with ALCL.     

不典型恶性淋巴瘤三例误诊原因分析

目的分析不典型恶性淋巴瘤3例误诊原因,总结防范措施。方法回顾性分析误诊为其他疾病的不典型恶性淋巴瘤3例的临床资料。结果3例均因发热就诊,病初均行相关检查未能明确诊断,分别误诊为结核性心包炎、胃体黏膜慢性炎伴溃疡、泌尿系感染,均予对症处理,病情无明显好转。为进一步明确诊断行穿刺活检,1例确诊为霍奇金淋巴瘤,2例确诊为非霍奇金淋巴瘤,给予对症治疗,其中1例完成化疗后临床治愈,1例化疗过程中出现肾损伤于半年后死亡,1例治疗18个月后病情复发死亡。结论不典型恶性淋巴瘤临床表现特征不明显,不易鉴别诊断,提示临床应提高警惕,避免误诊。     

IEP方案治疗37例复发性、难治性非霍奇金淋巴瘤

[目的]研究复发性，难治性中高度恶性非零奇金淋巴瘤的解救治疗。[方法]37例复发性，难治性中高度恶性非霍奇金淋巴瘤病人用IEP方案治疗；异环磷酰胺（IFO）2g静脉点滴，第1-4天（同时使用美斯纳）；足叶乙甙（Vp-16)100mg，静脉点滴，第1-4天；顺铂30mg/m^2，静脉点滴，第1-3天；21-28天为1周期，连用2周期评定疗效。[结果]总缓解率为81.1%(30/37)。完全缓解率（CR）为35.1%(13/37)，部分缓解率为45.9%(17/37)。主要不良反应为骨髓抑制和脱发，白细胞减少发生率为83.8%，其中Ⅲ-Ⅳ度发生率占43.2%。血红蛋白及血小板减少发生率分别为37.8%和43.2%。脱发发生率为91.2%，其它不良反应湛和见。[结论]IEP方案可作为复发性，难治性中高度恶性淋巴瘤的解救治疗。     

美罗华联合化疗对非霍奇金淋巴瘤疗效的Meta分析

目的综合评价美罗华联合化疗对非霍奇金淋巴瘤的疗效。方法应用国际Cochrance协作网的系统评价方法,对关于非霍奇金淋巴瘤接受美罗华联合化疗组与单纯化疗组疗效比较的随机和半随机试验研究的结果进行系统评价。结果共检索到6个试验包括1132例患者,美罗华联合化疗组的完全缓解率高于单纯化疗组(OR=4.15,95%CI2.36～7.30,P<0.00001),经异质性检验显示6个试验存在异质性(χ2=15.15,P=0.010)。采用随机效应模型进行综合分析。敏感性分析亦证实美罗华联合化疗的疗效优于单纯化疗组(OR=5.14,95%CI3.38～7.81,P<0.00001)。结论美罗华联合化疗对非霍奇金淋巴瘤有一定疗效,有必要开展更多设计良好的临床随机对照试验,进一步证明其临床效果。     

法玛新治疗中晚期恶性肿瘤的临床观察

目的　验证合资产品法玛新 (EPI)治疗非霍奇金淋巴瘤 (NHL)和乳腺癌的疗效和安全性。方法　乳腺癌 :5 -Fu 5 0 0mg/m2ivgttd1,EPI 60mg/m2 ivd1,CTX 60 0mg/m2 ivd1;NHL :CTX 60 0mg/m2 ivd1,EPI 60mg/m2 ivd1,VCR 1.4mg/m2 ivdl,PDN 60mg/m2 pod1～ 5。 2 1天为 1周期 ,治疗 2周期。结果　本组 3 0例中 ,总有效率 (CR +PR) 67%。NHL的疗效为 75 % ,其中CR 5例 ,占 2 5 %。乳腺癌的有效率为 5 0 % ,CR 1例 ,占 10 %。毒性主要表现为骨髓抑制和脱发 ,白细胞计数下降发生率两周期分别为 90 %和 93 % ,Ⅲ～Ⅳ度分别为 3 3 4%和 2 6 7%。消化道反应轻微 ,未发现肝肾功能及心电图 (EKG)异常。结论　法玛新具有较好的疗效和安全性